Advertisement
Screener

Neurogene Inc. (NGNE) Graph

NGNE Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development $25.47M; Operating expenses $36.67M; Income tax (m).
  • 2026-03-31: Revenue (m); Research and development $25.15M; Operating expenses $33.35M; Income tax (m).
  • 2025-12-31: Revenue $0.00*; Research and development $20.64M*; Operating expenses $27.53M*; Income tax (m).
  • 2025-09-30: Revenue $0.00; Research and development $17.24M; Operating expenses $23.80M; Income tax (m).

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$25.47M$36.67M(m)-$34.49M
2026-03-31(m)$25.15M$33.35M(m)-$30.93M
2025-12-31$0.00*$20.64M*$27.53M*(m)-$24.73M*
2025-09-30$0.00$17.24M$23.80M(m)-$20.95M
2025-06-30$0.00$19.37M$26.08M(m)-$22.02M
2025-03-31(m)$17.76M$25.92M(m)-$22.65M
2024-09-30$0.00$16.29M$22.18M(m)-$20.22M
2024-06-30$925.00K$15.74M$21.06M(m)-$18.49M
2024-03-31(m)$13.54M$18.78M(m)-$16.92M
2023-09-30$0.00$11.61M$15.22M(m)-$14.58M
2023-06-30$0.00$10.32M$12.60M(m)-$11.86M
2023-03-31(m)$10.28M$13.04M(m)-$12.26M
2022-09-30(m)$9.47M$13.61M(m)-$13.07M
2022-06-30(m)$10.96M$15.87M(m)-$15.69M
2022-03-31(m)$10.70M$15.37M(m)-$15.35M
2021-09-30(m)$9.90M$15.45M(m)-$15.45M
2021-06-30(m)$9.82M$15.12M(m)-$15.13M
2021-03-31(m)$9.71M(m)(m)-$14.95M
2020-09-30(m)$6.22M(m)(m)-$2.25M
2020-06-30(m)$4.84M$9.77M(m)-$9.75M
2020-03-31(m)$5.50M$9.07M(m)-$8.64M
2019-12-31(m)(m)$8.36M*(m)(m)
2019-09-30(m)(m)$59.52M(m)-$59.13M
2019-06-30(m)(m)$428.00K(m)-$1.00K
2019-03-31(m)$104.00K$2.66M(m)-$2.21M
2018-12-31(m)$2.57M*(m)(m)(m)
2018-09-30(m)$10.71M$15.20M(m)-$14.99M
2018-06-30$25.00M$18.00M$22.31M(m)$2.92M
2018-03-31(m)$10.51M$14.82M(m)-$14.62M
2017-09-30(m)$8.46M$12.07M(m)-$11.83M
2017-06-30(m)$10.47M$13.99M(m)-$13.77M
2017-03-31(m)$5.78M$8.52M(m)-$8.32M
2016-09-30(m)$6.13M$8.28M(m)-$8.15M
2016-06-30(m)$9.23M$11.06M(m)-$10.90M
2016-03-31(m)$4.88M$6.83M(m)-$6.71M
2015-09-30(m)$3.69M$4.92M(m)-$5.04M
2015-06-30(m)$3.62M$4.79M(m)-$4.75M
2015-03-31(m)$4.57M$6.04M(m)-$6.41M
2014-09-30(m)$5.32M$6.31M-$222.00-$6.28M
2014-06-30(m)$4.55M$5.63M(m)-$5.42M
2014-03-31(m)$1.88M$2.62M(m)-$4.23M
2013-09-30(m)$3.03M$3.42M-$5.04K-$3.37M
2013-06-30(m)$1.25M$1.62M(m)-$811.50K
2013-03-31(m)$572.97K$996.83K(m)-$1.01M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30(m)$50.62M$70.02M-$65.42M
2025-06-30$0.00$37.13M$52.00M-$44.66M
2024-06-30$925.00K$29.29M$39.84M-$35.41M
2023-06-30$0.00$20.60M$25.63M-$24.12M
2022-06-30(m)$21.66M$31.24M-$31.04M
2021-06-30(m)$19.51M$30.07M-$30.08M
2020-06-30(m)$10.34M$18.84M-$18.39M
2019-06-30(m)(m)$3.09M-$2.21M
2018-06-30$25.00M$28.50M$37.13M-$11.71M
2017-06-30(m)$16.25M$22.52M-$22.08M
2016-06-30(m)$14.12M$17.90M-$17.61M
2015-06-30(m)$8.19M$10.83M-$11.16M
2014-06-30(m)$6.43M$8.25M-$9.65M
2013-06-30(m)$1.82M$2.61M-$1.82M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$0.00$54.37M$75.80M(m)-$65.62M
2024-09-30$925.00K$45.57M$62.02M(m)-$55.63M
2023-09-30$0.00$32.21M$40.85M(m)-$38.70M
2022-09-30(m)$31.13M$44.85M(m)-$44.11M
2021-09-30(m)$29.40M$45.52M(m)-$45.52M
2020-09-30(m)$16.56M(m)(m)-$20.64M
2019-09-30(m)(m)$62.60M(m)-$61.34M
2018-09-30$25.00M$39.22M$52.32M(m)-$26.70M
2017-09-30(m)$24.71M$34.59M(m)-$33.91M
2016-09-30(m)$20.25M$26.18M(m)-$25.76M
2015-09-30(m)$11.87M$15.75M(m)-$16.20M
2014-09-30(m)$11.75M$14.56M-$222.00-$15.94M
2013-09-30(m)$4.85M$5.93M-$5.04K-$5.19M

Revenue and expense 10 month

Period endNet income
2014-12-31-$24.03M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$0.00$75.01M$103.33M$0.00-$90.35M
2024-12-31$925.00K$60.92M$83.53M$0.00-$75.14M
2023-12-31$0.00$44.39M$55.58M(m)-$36.32M
2022-12-31(m)$47.51M$56.52M(m)-$55.19M
2021-12-31(m)$39.16M$60.70M(m)-$60.69M
2020-12-31(m)(m)(m)(m)-$33.28M
2019-12-31(m)(m)$70.96M(m)-$69.44M
2018-12-31$25.00M$41.79M$57.62M(m)-$31.59M
2017-12-31(m)$36.27M$51.12M(m)-$50.18M
2016-12-31(m)$28.38M$37.65M$0.00-$37.00M
2015-12-31(m)$15.80M$21.34M$0.00-$21.86M
2014-12-31(m)$18.08M$22.38M$0.00-$24.03M
2013-12-31(m)$7.60M$9.38M-$5.00K-$8.73M
2012-12-31(m)$6.05M$7.68M$42.29K-$7.71M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
CorMedix Inc. (CRMD)United States$0.605B3.25
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
Monopar Therapeutics (MNPR)United States$0.598B-34.82
Altimmune, Inc. (ALT)United States$0.593B-6.43
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76